Skip to main content
SpringerLink
Log in

Diabetes

Add-on to metformin in T2DM—linagliptin or glimepiride?

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475–483 (2012).

    Article  CAS  Google Scholar 

  2. Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577–1596 (2012).

    Article  CAS  Google Scholar 

  3. [No authors listed] U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44, 1249–1258 (1995).

  4. Maedler, K. et al. Sulfonylurea induced cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90, 501–506 (2005).

    Article  CAS  Google Scholar 

  5. U.K. Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50, 1140–1147 (2007).

  6. Landstedt-Hallin, L., Adamson, U. & Lins, P. E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 84, 3140–3145 (1999).

    CAS  PubMed  Google Scholar 

  7. Ahrén, B. et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1236–1243 (2009).

    Article  Google Scholar 

  8. Sivertsen, J., Rosenmeier, J., Holst, J. J. & Vilsbøll, T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209–222 (2012).

    Article  CAS  Google Scholar 

  9. Engbersen, R. et al. Differential effects of sulfonylurea derivatives on vascular ATP-sensitive potassium channels. Eur. J. Pharmacol. 681, 75–79 (2012).

    Article  CAS  Google Scholar 

  10. Bonds, D. E. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340, b4909 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, Copenhagen, 2400, Denmark

    Mikkel Christensen

  2. Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, DK-2900, Denmark

    Filip K. Knop

Authors
  1. Mikkel Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filip K. Knop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filip K. Knop.

Ethics declarations

Competing interests

Filip K. Knop declares that he has received speakers bureau from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Sharp & Dohme, Novartis, Novo Nordisk and Ono Pharmaceuticals. Mikkel Christensen declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensen, M., Knop, F. Add-on to metformin in T2DM—linagliptin or glimepiride?. Nat Rev Endocrinol 8, 576–578 (2012). https://doi.org/10.1038/nrendo.2012.163

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.163

  • Springer Nature Limited

Search

Navigation